alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
<PAGE>   1
                                                                     EXHIBIT 5.1



                       [Letterhead of Getty Images, Inc.]




                                 August 12, 1999



Getty Images, Inc.
2101 Fourth Avenue, Fifth Floor
Seattle, Washington 98121


                               Getty Images, Inc.
         Registration Statement on Form S-3 (Registration No. 333-79155)


Ladies and Gentlemen:

     As counsel to Getty Images, Inc., a Delaware corporation (the "Company"), I
am rendering this opinion in connection with the registration by the Company
pursuant to the above-referenced Registration Statement on Form S-3 (as amended,
the "Registration Statement") under the Securities Act of 1933, as amended, of
up to 4,957,817 shares of common stock, par value $0.01 per share (the
"Shares").

     As such counsel and in connection with the opinions expressed below, I have
examined a copy of the Registration Statement and the originals, or copies,
identified to my satisfaction, of such corporate records of the Company,
certificates of public officials, officers of the Company and other persons, and
such other documents, agreements and instruments as I have deemed necessary as a
basis for the opinions hereinafter expressed. In my examinations, I have assumed
the genuineness of all signatures, the authenticity of all documents submitted
to me as originals and the conformity with the originals of all documents
submitted to me as copies. In expressing the opinions set forth below, I have
also relied on certain certificates of officers of the Company and certificates
of public officials.

     My opinions expressed below are limited to the laws of the State of
Delaware and the federal law of the United States, and I do not express any
opinion herein concerning any other law.

<PAGE>   2

     Based on the foregoing and having regard for such legal considerations as I
have deemed relevant, I am of the opinion that the Shares have been duly
authorized and are validly issued, fully paid and non-assessable.

     I hereby consent to the use of this opinion as an exhibit to the
Registration Statement and to my reference under the caption "Legal Matters"
therein.


                                        Very truly yours,

                                        /s/ Suzanne L. Page
                                            ------------------------------------
                                        Associate General Counsel


cc: William H. Hinman, Jr., Shearman & Sterling
    Mark A. B. Carlson, Shearman & Sterling
§ 225.1 Current good manufacturing practice. ( a ) Section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act provides that a drug (including a drug contained in a medicated feed) shall be deemed to be adulterated if the methods used in, or the facilities or controls used for, its manufacture, processing, packing, or holding do not conform to or are not operated or administered in conformity with current good manufacturing practice to assure that such drug meets the requirement of the act as to safety and has the identity and strength, and meets the quality and purity characteristics, which it purports or is represented to possess.
( b ) ( 1 ) The provisions of this part set forth the criteria for determining whether the manufacture of a medicated feed is in compliance with current good manufacturing practice. These regulations shall apply to all types of facilities and equipment used in the production of medicated feeds, and they shall also govern those instances in which failure to adhere to the regulations has caused nonmedicated feeds that are manufactured, processed, packed, or held to be adulterated. In such cases, the medicated feed shall be deemed to be adulterated within the meaning of section 501(a)(2)(B) of the act, and the nonmedicated feed shall be deemed to be adulterated within the meaning of section 402(a)(2)(C)(ii) of the act.
( 2 ) The regulations in §§ 225.10 through 225.115 apply to facilities manufacturing one or more medicated feeds for which an approved medicated feed mill license is required. The regulations in §§ 225.120 through 225.202 apply to facilities manufacturing solely medicated feeds for which an approved license is not required.
( c ) In addition to the recordkeeping requirements in this part, Type B and Type C medicated feeds made from Type A articles or Type B feeds under approved NADAs or indexed listings and a medicated feed mill license are subject to the requirements of § 510.301 of this chapter.
[41 FR 52618, Nov. 30, 1976, as amended at 51 FR 7389, Mar. 3, 1986; 64 FR 63203, Nov. 19, 1999; 72 FR 69120, Dec. 6, 2007; 79 FR 3739, Jan. 23, 2014]
NOT FINAL UNTIL TIME EXPIRES TO FILE REHEARING

MOTION AND, IF FILED, DETERMINED

IN THE DISTRICT COURT OF APPEAL

OF FLORIDA

SECOND DISTRICT

THEODORE DAVIS, JR., )

)

Appellant, )

)

v. ) Case No. 2D17-4009

)

STATE OF FLORIDA, )

)

Appellee. )

___________________________________)

Opinion filed March 7, 2018.

Appeal pursuant to Fla. R. App. P.

9.141(b)(2) from the Circuit Court 

for Hillsborough County; Tom Barber,

Judge.

Theodore Davis, Jr., pro se.

PER CURIAM.

Affirmed. See Johnson v. State, 60 So. 3d 1045 (Fla. 2011); Dale v. 

State, 703 So. 2d 1045 (Fla. 1997); Hughes v. State, 22 So. 3d 132 (Fla. 2d DCA 2009); 

Steward v. State, 931 So. 2d 133 (Fla. 2d DCA 2006); Shortridge v. State, 884 So. 2d 

321 (Fla. 2d DCA 2004); Brown v. State, 827 So. 2d 1054 (Fla. 2d DCA 2002); Walls v. 

State, 730 So. 2d 294 (Fla. 1st DCA 1999).

NORTHCUTT, LUCAS, and SALARIO, JJ., Concur.
§ 524.981a Fluocinolone cream. ( a ) *Specifications.* The drug contains 0.025 percent fluocinolone acetonide.
( b ) *Sponsor.* See No. 099207 in § 510.600(c) of this chapter.
( c ) *Conditions of use in dogs* — ( 1 ) *Amount.* A small amount is applied to the affected area two or three times daily.
( 2 ) *Indications for use.* For the relief of pruritis and inflammation associated with certain superficial acute and chronic dermatoses. It is used in the treatment of allergic and acute moist dermatitis and for the relief of superficial inflammation caused by chemical burns and physical abrasions.
( 3 ) Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[40 FR 13873, Mar. 27, 1975, as amended at 62 FR 40932, July 31, 1997; 79 FR 10968, Feb. 27, 2014]
[No. 16222-2-III.

Division Three.

December 23, 1997.]

#### Scott Tollackson, *Plaintiff,*Jim Harum, *Appellant,*v. Chelan County, *Respondent.*

Appeal from a judgment of the Superior Court for Chelan County, No. 95-2-00625-1, John E. Bridges, J., entered April 30, 1996. *Affirmed*by unpublished opinion per Kurtz, J., concurred in by Brown and Kato, JJ.
§ 520.540c Dexamethasone chewable tablets. ( a ) *Specifications.* Each half-scored tablet contains 0.25 milligram of dexamethasone.
( b ) *Sponsor.* See No. 051031 in § 510.600(c) of this chapter.
( c ) *Conditions of use in dogs* — ( 1 ) *Amount.* Administer by free-choice feeding or crumbled over food 0.25 to 1.25 milligrams daily in single or two divided doses until response is noted or 7 days have elapsed. When response is attained, dosage should be gradually reduced by 0.125 milligram per day until maintenance level is achieved.
( 2 ) *Indications for use.* As supportive therapy in nonspecific dermatosis and inflammatory conditions.
( 3 ) *Limitations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[44 FR 7130, Feb. 6, 1979, as amended at 56 FR 50653, Oct. 8, 1991; 60 FR 55659, Nov. 2, 1995; 79 FR 28820, May 20, 2014; 82 FR 11508, Feb. 24, 2017]
§ 524.155 Bacitracin, neomycin, polymyxin B, and hydrocortisone ophthalmic ointment. ( a ) *Specifications.* Each gram of ointment contains 400 units of bacitracin zinc, 5 milligrams (mg) of neomycin sulfate (equivalent to 3.5 mg of neomycin sulfate), 10,000 units of polymyxin B sulfate, and10 mg of hydrocortisone.
( b ) *Sponsors.* See Nos. 000061 and 043264 in § 510.600(c) of this chapter.
( c ) *Conditions of use in dogs and cats* — ( 1 ) *Amount.* Apply a thin film over the cornea three or four times daily.
( 2 ) *Indications for use.* For treating acute or chronic conjunctivitis caused by susceptible organisms.
( 3 ) *Limitations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[57 FR 37333, Aug. 18, 1992, as amended at 61 FR 8873, Mar. 6, 1996; 62 FR 61626, Nov. 19, 1997; 77 FR 64717, Oct. 23, 2012; 79 FR 10967, Feb. 27, 2014]
§ 522.1066 Glycopyrrolate. ( a ) *Specifications.* Each milliliter of solution contains 0.2 milligram glycopyrrolate.
( b ) *Sponsors.* See Nos. 054771 and 069043 in § 510.600(c) of this chapter.
( c ) *Conditions of use in dogs and cats* — ( 1 ) *Amount.* 5 micrograms per pound of body weight (0.25 milliliter per 10 pounds of body weight) by intravenous, intramuscular, or subcutaneous injection in dogs or by intramuscular injection in cats.
( 2 ) *Indications for use.* As a preanesthetic agent.
( 3 ) *Limitations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[71 FR 64451, Nov. 2, 2006, as amended at 78 FR 17597, Mar. 22, 2013; 79 FR 16189, Mar. 25, 2014; 81 FR 17608, Mar. 30, 2016]
#### People of the State of Illinois, Plaintiff-Appellee, v. Bonnie Mae Welsch, Defendant-Appellant.

Gen. No. 52,726. (Abstract of Decision.)

First District, Third Division.

June 5, 1969.

Gerald W. Getty, Public Defender of Cook County, of Chicago (Herbert Becker, Norman W. Fishman and James J. Doherty, Assistant Public Defenders, of counsel), for appellant;

Edward V. Hanrahan, State’s Attorney of Cook County, of Chicago (Elmer C. Kissane and James J. Meehan, Assistant State’s Attorneys, of counsel), for appellee.

Opinion by

MR. JUSTICE SCHWARTZ.

Not to be published in full.
§ 19.21 Duty to report violations. ( a ) The Office of Internal Affairs, Office of the Commissioner, is responsible for obtaining factual information for the Food and Drug Administration on any matter relating to allegations of misconduct, impropriety, conflict of interest, or other violations of Federal statutes by agency personnel.
( b ) Any Food and Drug Administration employee who has factual information showing or who otherwise believes that any present or former Food and Drug Administration employee has violated or is violating any provision of this subpart or of 45 CFR parts 73 or 73a or of any statute listed in appendix A to 45 CFR part 73 should report such information directly to the Office of Internal Affairs. Any such reports shall be in writing or shall with the assistance of the Office of Internal Affairs, be reduced to writing, and shall be promptly investigated.
( c ) Any report pursuant to paragraph (b) of this section and any records relating to an investigation of such reports shall be maintained in strict confidence in the files of the Office of Internal Affairs, shall be exempt from public disclosure, and may be reviewed only by authorized Food and Drug Administration employees who are required to do so in the performance of their duties.
[42 FR 15615, Mar. 22, 1977, as amended at 46 FR 8456, Jan. 27, 1981; 50 FR 52278, Dec. 23, 1985; 60 FR 47478, Sept. 13, 1995]
Editorial Note on Part 177
Editorial Note: Nomenclature changes to part 177 appear at 61 FR 14482, Apr. 2, 1996; 66 FR 56035, Nov. 6, 2001; 66 FR 66742, Dec. 27, 2001; 68 FR 15355, Mar. 31, 2003; 70 FR 72074, Dec. 1, 2005; and 81 FR 49896, July 29, 2016.

§ 177.1240 1,4-Cyclohexylene dimethylene terephthalate and 1,4-cyclohexylene dimethylene isophthalate copolymer. Copolymer of 1,4-cyclohexylene dimethylene terephthalate and 1,4-cyclohexylene dimethylene isophthalate may be safely used as an article or component of articles used in producing, manufacturing, packing, processing, preparing, treating, packaging, transporting, or holding food, subject to the provisions of this section: ( a ) The copolymer is a basic polyester produced by the catalytic condensation of dimethyl terephthalate and dimethyl isophthalate with 1,4-cyclohexanedimethanol, to which may have been added certain optional substances required in its production or added to impart desired physical and technical properties.
( b ) The quantity of any optional substance employed in the production of the copolymer does not exceed the amount reasonably required to accomplish the intended physical or technical effect or any limitation further provided.
( c ) Any substance employed in the production of the copolymer that is the subject of a regulation in parts 174, 175, 176, 177, 178 and § 179.45 of this chapter conforms with any specification in such regulation.
( d ) Substances employed in the production of the copolymer include: ( 1 ) Substances generally recognized as safe in food.
( 2 ) Substances subject to prior sanction or approval for use in the copoly-mer and used in accordance with such sanction or approval.
( 3 ) Substances which by regulation in parts 174, 175, 176, 177, 178 and § 179.45 of this chapter may be safely used as components of resinous or polymeric coatings and film used as food-contact surfaces, subject to the provisions of such regulation.
( e ) The copolymer conforms with the following specifications: ( 1 ) The copolymer, when extracted with distilled water at reflux temperature for 2 hours, yields total extractives not to exceed 0.05 percent.
( 2 ) The copolymer, when extracted with ethyl acetate at reflux temperature for 2 hours, yields total extractives not to exceed 0.7 percent.
( 3 ) The copolymer, when extracted with *n-*hexane at reflux temperature for 2 hours, yields total extractives not to exceed 0.05 percent.
[42 FR 14572, Mar. 15, 1977; 49 FR 5748, Feb. 15, 1984, as amended at 55 FR 34555, Aug. 23, 1990]
Editorial Note on Part 170
Editorial Note: Nomenclature changes to part 170 appear at 66 FR 56035, Nov. 6, 2001, and 69 FR 13717, Mar. 24, 2004.

§ 170.6 Opinion letters on food additive status. ( a ) Over the years the Food and Drug Administration has given informal written opinions to inquiries as to the safety of articles intended for use as components of, or in contact with, food. Prior to the enactment of the Food Additives Amendment of 1958 (Pub. L. 85-929; Sept. 6, 1958), these opinions were given pursuant to section 402(a)(1) of the Federal Food, Drug, and Cosmetic Act, which reads in part: “A food shall be deemed to be adulterated if it bears or contains any poisonous or deleterious substance which may render it injurious to health”.
( b ) Since enactment of the Food Additives Amendment, the Food and Drug Administration has advised such inquirers that an article: ( 1 ) Is a food additive within the meaning of section 201(s) of the act; or
( 2 ) Is generally recognized as safe (GRAS); or
( 3 ) Has prior sanction or approval under that amendment; or
( 4 ) Is not a food additive under the conditions of intended use.
( c ) In the interest of the public health, such articles which have been considered in the past by the Food and Drug Administration to be safe under the provisions of section 402(a)(1), or to be generally recognized as safe for their intended use, or to have prior sanction or approval, or not to be food additives under the conditions of intended use, must be reexamined in the light of current scientific information and current principles for evaluating the safety of food additives if their use is to be continued.
( d ) Because of the time span involved, copies of many of the letters in which the Food and Drug Administration has expressed an informal opinion concerning the status of such articles may no longer be in the file of the Food and Drug Administration. In the absence of information concerning the names and uses made of all the articles referred to in such letters, their safety of use cannot be reexamined. For this reason all food additive status opinions of the kind described in paragraph (c) of this section given by the Food and Drug Administration are hereby revoked.
( e ) The prior opinions of the kind described in paragraph (c) of this section will be replaced by qualified and current opinions if the recipient of each such letter forwards a copy of each to the Department of Health and Human Services, Food and Drug Administration, Center for Food Safety and Applied Nutrition, 5001 Campus Dr., College Park, MD 20740, along with a copy of his letter of inquiry, on or before July 23, 1970.
( f ) This section does not apply to food additive status opinion letters pertaining to articles that were considered by the Food and Drug Administration to be food additives nor to articles included in regulations in parts 170 through 189 of this chapter if the articles are used in accordance with the requirements of such regulations.
[42 FR 14483, Mar. 15, 1977, as amended at 54 FR 24896, June 12, 1989; 81 FR 49896, July 29, 2016]
Exhibit



Exhibit 10.2



SECOND AMENDMENT TO PURCHASE AND SALE AGREEMENT
THIS SECOND AMENDMENT TO PURCHASE AND SALE AGREEMENT (the “Amendment”) is made and entered into as of February 15, 2017, by and between Cardiovascular Systems, Inc., a Delaware corporation (“Seller”), and Krishna Holdings, LLC, a Minnesota limited liability company and its assigns (“Purchaser”).
RECITALS:
A.Purchaser and Seller are parties to that certain Purchase and Sale Agreement dated as of December 29, 2016, as amended by that certain First Amendment to Purchase Agreement dated February 2, 2017 (collectively the “Purchase Agreement”).
B.    Purchaser and Seller desire to amend the Purchase Agreement to extend the expiration of the Inspection Period.
AGREEMENTS:
NOW, THEREFORE, in consideration of the foregoing Recitals, which, by this reference thereto, are hereby incorporated into the body of this Amendment, and for other good, fair and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties hereby agree as follows:
1.    Defined Terms.  Capitalized terms utilized in this Amendment and not separately defined herein shall have the meanings ascribed to them in the Purchase Agreement.
2.    Extension of Expiration of Inspection Period.  The definition of Inspection Period in Section 5.03 is hereby amended by deleting the expiration date of "February 15, 2017," and replacing it with "February 22, 2017."
3.    Miscellaneous.  Except as expressly set forth in this Amendment, the Purchase Agreement remains unmodified and in full force and effect.  The provisions of this Amendment inure to the benefit of Purchaser and Seller and shall be binding on their successors and assigns.
4.    Counterparts.  This Amendment may be executed in counterparts which taken together shall be considered one and the same instrument.  Such counterparts may be evidenced by facsimile or electronic (PDF) signature pages.
IN WITNESS WHEREOF, Seller and Purchaser have executed this Amendment as of the date first above written.









SELLER:
Cardiovascular Systems, Inc.


By:    _/s/ Jeffrey S. Points___________


Name:    __Jeffrey S. Points____________


Title:    _Corporate Controller & Treasurer




PURCHASER:
Krishna Holdings, LLC


By:    _/s/ Ashish Aggarwal __________


Name:    ___ Ashish Aggarwal ___________


Title:    __Chief Manager_______________
Exhibit 23

 

**Consentof Independent Registered Public Accounting Firm**

 

We consent to theincorporation by reference in the Registration Statements on Form S-8 (No. 333-155875and 333-130041)****of Retractable Technologies, Inc.of our report dated March 31, 2010 relating to our audit of the financialstatements and financial statement schedule, which appear in this Annual Reporton Form 10-K of Retractable Technologies, Inc. for the year ended December 31,2009.

 
|   | /s/ CF & Co.,  L.L.P. |   |
|--------|--------------------------------|--------|
|   | CF & Co.,  L.L.P.     |   |

 

Dallas, Texas

March 31, 2010

 

----
**Exhibit 99.3**

 
|  | • Ernst & Young LLP  220 South Sixth Street, Ste 1400  Minneapolis, MN 55402-4509 | • Phone: (612) 343-1000  www.ey.com |
|--|-------------------------------------------------------------------------------------------------|-----------------------------------------------|

 

Report of Independent Registered PublicAccounting Firm

 

Target National BankIts Officers and DirectorsAs Servicer

 

We have examined management’s assertion in the accompanying report,Report of Management on Compliance, dated February 15, 2006, that TargetNational Bank (the Bank), as Servicer, complied inall material respects with the administration and servicing requirements ofArticle III, Article IV, and Section 8.8 of the Amended and Restated Poolingand Servicing Agreement, dated April 28, 2000, and the applicable provisions ofthe Series 2002-1 Supplement, dated July 2, 2002, and the Series 2005-1Supplement, dated November 9, 2005, to the Target Credit Card Master Trust, asset forth in Exhibit A to the accompanying Report of Management on Complianceas of December 31, 2005, and for the fiscal year then ended. The Bank’smanagement is responsible for the Bank’s compliance with those requirements.Our responsibility is to express an opinion on management’s assertion based onour examination.

 

Our examination was conducted in accordance with attestation standardsestablished by the Public Company Accounting Oversight Board (United States)and, accordingly, included examining, on a test basis, evidence about the Bank’scompliance with those requirements and performing such other procedures as weconsidered necessary in the circumstances. We believe that our examination providesa reasonable basis for our opinion. Our examination does not provide a legaldetermination on the Bank’s compliance with specified requirements.

 

In our opinion, management’s assertion that the Bank complied with theaforementioned requirements as of and for the year ended December 31, 2005, isfairly stated, in all material respects.

 
|              |        |
|-------------------|--------|
| February 15, 2006 |   |

 

A Member Practice of Ernst & Young Global

 

----
# INDAGO

VERTICAL TAKE-OFF AND LANDING (VTOL) SYSTEM

FOR COMMERICAL AND MILITARY MARKETS

# HANDCONTROLLER

• For small UAS; fixed wing and VTOL

• Stand-alone, unt ethered opera tion

• Secure digital dat a link

• Window s 8.1 based opera ting sy stem

• Onboard rec ording of HD video and stills

• Small erg onomic design with larg e outdoor

readable touchscr een

• Rugg edized and wea ther resis tant

• Lightw eight: 2.7 -3.3 lbs.

• Long run time (4

- 8 hours) 

# FEATURES

• Man packable, compact folding design

• Setup in 60 seconds, airborne in 2.5 minutes

• Whisper quiet, rugg ed, all-wea ther capability

• Configur able Failsa fe behavior s

• Opera tion via handcon troller and/or full Virtual

CockpitTM GCS

• Hot-s wappable payload options for ISR, search &

rescue, inspection and agriculture

• Industr y-leading image st abilization with vision

tracking



### Specifications

Endurance Up to 50 minutes with payload

Payload Multiple, hot-s wappable payloads

Rang e 1

- 5 km (radio and antenna dependent)

Dimensions 32 x 32 x 7 in (12 x 9 x 7 folded)

W eight 5 lbs. (2,300g) with ION payload

Oper ating Altitude 10-500 ft AGL (typical)

GCS t ouchscreen handcon troller or

lap top-based Virtual Cockpit 

### Lockheed Martin

Mi ssion Sy stems and Tr aining (MS T)

300 M St reeet, SE

Wa shington, D. C. 20 003

www.lockheedmartin.com/unmanned

PH: (801) 788-3200

© 2015 Lockheed Martin Corporation

PIRA# OWG20131000236971 

# EXPLORE.

EXAMINE.

INVESTIGATE.